Research and Markets (http://www.researchandmarkets.com/research/nqvgj5/key_findings_from) has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Asthma" to their offering.
In February 2010, the FDA announced new controls for long-acting beta2 agonist (LABA)-containing drugs that may alter the asthma treatment paradigm. Concerned about an increased risk of asthma-related death with LABA-containing drugs, the FDA advises that fixed-dose combinations of LABAs and inhaled corticosteroids (ICSs) be reserved for patients whose asthma remains uncontrolled despite treatment with single-agent ICSs. The revised guidelines have been an impetus for physicians to reevaluate their reliance on LABA/ICS combinations to treat asthma.
It remains to be seen whether LABA/ICS combinations, which are frequently used for first-line therapy, will continue to be used in this manner. Indeed, many LABA/ICS combinations in development are no longer expected to be launched in the United States given the burden of safety trials now expected by the FDA for LABA-containing drugs.
This report examines patient-level claims data to quantify the use of asthma maintenance therapies, including the LABA/ICS combinations GlaxoSmithKline's Advair, AstraZeneca/Astellas's Symbicort, and Merck's Dulera, as well as many single-agent ICSs. We determine the share of each drug by line of therapy, evaluate the therapy flow, and analyze why key drugs are chosen over others. We provide valuable insight for any company looking to take advantage of the competitive openings resulting from the increased concern surrounding LABA/ICS combinations.
Key Topics Covered:
2. Key Findings for Newly Diagnosed Patients
3. Key Findings for Recently Treated Patients
4. Key Findings by Product
5. Appendix: Methodology
For more information visit http://www.researchandmarkets.com/research/nqvgj5/key_findings_from
Source: Decision Resources, IncBusiness Wire
Last updated on: 08/10/2012